Literature DB >> 34993609

The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients.

Ralph Hsiao1, Alicia Chow1, Wouter P Kluijfhout1, Pim J Bongers1, Raoul Verzijl1, Ur Metser2, Patrick Veit-Haibach2, Jesse D Pasternak3.   

Abstract

PURPOSE: Oncology patients undergoing positron emission tomography/computed tomography (PET/CT) occasionally show discrete adrenal [18F]-fluorodeoxyglucose (FDG) uptake without an associated nodule on CT, leaving the clinician uncertain about the need to proceed with biopsy or surgical referral. This study aimed to identify the prevalence of this radiological finding and to evaluate the effectiveness of FDG uptake values in risk stratification for adrenal metastasis.
METHODS: From 2014 to 2015, oncology patients who underwent FDG-PET/CT and demonstrated elevated FDG uptake in the adrenal gland without discrete nodularity on cross-sectional imaging were included in a retrospective cohort analysis. Clinical records and FDG-PET/CT scans were reviewed for clinicopathological data, follow-up data, SUVmax (highest SUV of either adrenal gland), and SUVratio (SUVmax/background liver uptake). A receiver operating characteristic analysis was conducted to evaluate the associations between SUV values and the progression to adrenal metastasis.
RESULTS: Of 3040 oncology patients who underwent FDG-PET/CT scans, 92 (3.0%) showed elevated adrenal uptake without associated mass. From the final study cohort of 66 patients with comprehensive follow-up data, 5 patients (7.6%) developed evidence of adrenal metastasis. At SUVmax < 3.25 (AUC = 0.757) and SUVratio < 1.27 (AUC = 0.907), 34.8% and 60.6% of patients could be excluded with 100% negative predictive value, respectively.
CONCLUSIONS: Thresholds of SUVmax and SUVratio identified a significant proportion of patients who did not develop adrenal metastasis. In oncology patients who demonstrate increased adrenal FDG uptake without a discrete lesion on FDG-PET/CT, quantitative uptake values may be useful in selecting those not at risk of developing adrenal metastatic disease.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Adrenal metastasis; Computed tomography; Positron emission tomography; Standardized uptake value; Tumor staging

Mesh:

Substances:

Year:  2022        PMID: 34993609     DOI: 10.1007/s00423-021-02379-3

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   2.895


  32 in total

1.  Treatment outcomes of percutaneous radiofrequency ablation versus adrenalectomy for adrenal metastases: a retrospective comparative study.

Authors:  B Liu; C Mo; W Wang; J Ye; C Jiang; X Xie; J Huang; G Huang; H Long; X Xie
Journal:  J Endocrinol Invest       Date:  2020-03-12       Impact factor: 4.256

2.  Adrenal surgery for oligometastatic tumors improves survival in selected cases.

Authors:  P Tomasini; M-E Garcia; L Greillier; C Paladino; F Sebag; F Barlesi
Journal:  J Visc Surg       Date:  2016-09-15       Impact factor: 2.043

3.  Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.

Authors:  Haruo Watanabe; Masayuki Kanematsu; Satoshi Goshima; Hiroshi Kondo; Hiroshi Kawada; Yoshifumi Noda; Noriyuki Moriyama
Journal:  Ann Nucl Med       Date:  2013-04-27       Impact factor: 2.668

4.  Survival outcomes following adrenalectomy for isolated metastases to the adrenal gland.

Authors:  Jason Ramsingh; Patrick O'Dwyer; Carol Watson
Journal:  Eur J Surg Oncol       Date:  2019-01-04       Impact factor: 4.424

5.  Adrenalectomy for metastasis: long-term results and predictors of survival.

Authors:  Leonardo Solaini; Silvia Ministrini; Matteo Tomasoni; Giulia Merigo; Giacomo Gaverini; Giam Paolo Bertoloni; Guido A M Tiberio
Journal:  Endocrine       Date:  2015-04-12       Impact factor: 3.633

6.  18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer.

Authors:  Rakesh Kumar; Yan Xiu; Jian Q Yu; Amol Takalkar; Ghassan El-Haddad; Scott Potenta; Justin Kung; Hongming Zhuang; Abass Alavi
Journal:  J Nucl Med       Date:  2004-12       Impact factor: 10.057

7.  The outcomes of adrenalectomy for solitary adrenal metastasis: A 17-year single-center experience.

Authors:  Koji Hatano; Sayaka Horii; Yasutomo Nakai; Masashi Nakayama; Ken-Ichi Kakimoto; Kazuo Nishimura
Journal:  Asia Pac J Clin Oncol       Date:  2018-09-30       Impact factor: 2.601

8.  Laparoscopic adrenalectomy for isolated adrenal metastasis.

Authors:  Vivian E Strong; Michael D'Angelica; Laura Tang; Francesco Prete; Mithat Gönen; Daniel Coit; Karim A Touijer; Yuman Fong; Murray F Brennan
Journal:  Ann Surg Oncol       Date:  2007-07-31       Impact factor: 5.344

9.  Laparoscopic adrenalectomy for metastatic disease: Retrospective cohort with long-term, comprehensive follow-up.

Authors:  Frederick Thurston Drake; Toni Beninato; Maggie X Xiong; Nirav V Shah; Wouter P Kluijfhout; Timothy Feeney; Insoo Suh; Jessica E Gosnell; Wen T Shen; Quan-Yang Duh
Journal:  Surgery       Date:  2018-12-24       Impact factor: 3.982

10.  Laparoscopic adrenalectomy for isolated adrenal metastasis: the right thing to do and the right way to do it.

Authors:  Quan-Yang Duh
Journal:  Ann Surg Oncol       Date:  2007-09-25       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.